Paroni, Gabriela
Bolis, Marco
Zanetti, Adriana
Ubezio, Paolo http://orcid.org/0000-0003-0412-9891
Helin, Kristian
Staller, Peter
Gerlach, Lars Ole
Fratelli, Maddalena
Neve, Richard M.
Terao, Mineko
Garattini, Enrico
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (17058)
Article History
Received: 23 July 2018
Revised: 9 November 2018
Accepted: 19 November 2018
First Online: 11 December 2018
Compliance with ethical standards
:
: Richard M. Neve is an employee of Gilead Sciences which developed and patented the proprietary KDM5 inhibitors used in the present study. The remaining authors declare that they have no conflict of interest.